» Articles » PMID: 31331088

The Burden of Serious Fungal Infections in Kyrgyzstan

Overview
Journal J Fungi (Basel)
Date 2019 Jul 24
PMID 31331088
Citations 3
Authors
Affiliations
Soon will be listed here.
Abstract

Kyrgyzstan in Central Asia has a population of 6 million people who have high mortality rates for chronic lung diseases. The mountainous geography, widespread use of biomass fuels for cooking and indoor heating, and high rates of smoking are the major contributing factors. We have estimated the number of serious fungal infections in order to define the burden of these diseases in Kyrgyzstan. We estimated 774 cases of chronic pulmonary aspergillosis (CPA) as a sequel of tuberculosis (TB); CPA occurs as a sequel of multiple conditions, so a total prevalence of 3097 cases was estimated, which is among the highest rates in the world. An estimated 2205 patients have allergic bronchopulmonary aspergillosis (ABPA) and 2911 have severe asthma with fungal sensitization (SAFS), which may be an underestimate. There are approximately 292 cases of invasive aspergillosis annually. The number of adult women who get recurrent vulvovaginal candidiasis is 175,949. We approximated 787 cases of oral and 294 cases of esophageal candidiasis, 25 cases of cryptococcal meningitis, and 101 cases of pneumonia annually in HIV-positive patients. The incidence of candidemia was estimated at 300. We have estimated that a total of 185,961 people (3% of the population) have serious fungal infection in Kyrgyzstan. Given this burden, diagnostic improvements are necessary.

Citing Articles

Post-COVID pulmonary fungal infections: An unanticipated predicament or a ticking time bomb? Clinico-microbiological profile of cases encountered during the second wave of COVID-19 pandemic at a teaching hospital in the Himalayas with a brief....

Puri O, Bhatia M, Rekha U, Chakraborty D, Dua R, Dhar M J Family Med Prim Care. 2024; 12(12):3228-3235.

PMID: 38361892 PMC: 10866219. DOI: 10.4103/jfmpc.jfmpc_1073_23.


Addressing Microbial Resistance Worldwide: Challenges over Controlling Life-Threatening Fungal Infections.

Martins-Santana L, Rezende C, Rossi A, Martinez-Rossi N, Almeida F Pathogens. 2023; 12(2).

PMID: 36839565 PMC: 9961291. DOI: 10.3390/pathogens12020293.


Human Codon Usage: The Genetic Basis of Pathogen Latency.

Kanduc D Glob Med Genet. 2021; 8(3):109-115.

PMID: 34430963 PMC: 8378922. DOI: 10.1055/s-0041-1729753.

References
1.
Yang Y, Lo H, Hung C, Li Y . Effect of prolonged HAART on oral colonization with Candida and candidiasis. BMC Infect Dis. 2006; 6:8. PMC: 1360084. DOI: 10.1186/1471-2334-6-8. View

2.
Lowes D, Al-Shair K, Newton P, Morris J, Harris C, Rautemaa-Richardson R . Predictors of mortality in chronic pulmonary aspergillosis. Eur Respir J. 2017; 49(2). DOI: 10.1183/13993003.01062-2016. View

3.
Denning D, Chakrabarti A . Pulmonary and sinus fungal diseases in non-immunocompromised patients. Lancet Infect Dis. 2017; 17(11):e357-e366. DOI: 10.1016/S1473-3099(17)30309-2. View

4.
Denning D, Pleuvry A, Cole D . Global burden of chronic pulmonary aspergillosis as a sequel to pulmonary tuberculosis. Bull World Health Organ. 2012; 89(12):864-72. PMC: 3260898. DOI: 10.2471/BLT.11.089441. View

5.
Colombo A, Almeida Junior J, Slavin M, Chen S, Sorrell T . Candida and invasive mould diseases in non-neutropenic critically ill patients and patients with haematological cancer. Lancet Infect Dis. 2017; 17(11):e344-e356. DOI: 10.1016/S1473-3099(17)30304-3. View